Manufacturer Noven Therapeutics has issued a voluntary recall of three strengths of the patch, a topical (used on the skin) ADHD treatment. This is a class II recall, the most common type of recall, which means that there is a situation where use of the recalled medication may cause temporary or medically reversible adverse health consequences, but the likelihood of serious adverse effects is small. For more information on the different types of recalls, see our overview here. Who can recall a drug? A manufacturer can voluntarily recall their medication, or the Food and Drug Administration (FDA) can request or require that a manufacturer recall a particular medication.

Daytrana is a transdermal patch developed and marketed by Noven Pharmaceuticals, Inc. Industrial Dynamics Jay Forrester Pdf Editor. That was approved in April 2006. In the literature, Daytrana is most commonly. Shire is recalling more of its Daytrana patches for attention deficit hyperactivity disorder, possibly leading to the return of as many as 469,000 patches.

Step By Step Jquery Tutorial For Beginners Pdf. In this case, the manufacturer has voluntarily recalled four lots of 15 mg, 20 mg, and 30 mg patches. Why has been recalled?

The recall was initiated because some patches “do not meet the release liner removal specification.” This means that the liner may be more difficult than normal to remove when opening the packaging. When was the recall initiated? The affected lots of were recalled by the manufacturer on December 23, 2015. Are patients who have taken this medication being notified?